Should You Add Cyteir Therapeutics Inc (CYT) Stock to Your Portfolio Thursday?

Thursday, June 29, 2023 10:34 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Add Cyteir Therapeutics Inc (CYT) Stock to Your Portfolio Thursday?

Cyteir Therapeutics Inc (CYT) is around the top of the Healthcare sector according to InvestorsObserver. CYT received an overall rating of 50, which means that it scores higher than 50% of stocks. Additionally, Cyteir Therapeutics Inc scored a 74 in the Healthcare sector, ranking it higher than 74% of stocks in that sector.

CYT has an Overall Score of 50. Find out what this means to you and get the rest of the rankings on CYT!

See Full CYT Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 50 means the stock is more attractive than 50 percent of stocks. Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Cyteir Therapeutics Inc Stock Today?

Cyteir Therapeutics Inc (CYT) stock is trading at $1.85 as of 10:20 AM on Thursday, Jun 29, a rise of $0.11, or 6.32% from the previous closing price of $1.74. The stock has traded between $1.76 and $1.92 so far today. Volume today is light. So far 11,938 shares have traded compared to average volume of 39,787 shares. Click Here to get the full Stock Report for Cyteir Therapeutics Inc stock.